[Improvement of diabetic polyneuritis with naftidrofuryl. Preliminary results].
This study was a 6-month open trial of the effects of naftidrofuryl fumarate (600 mg/day orally) on the clinical and electrophysiological signs of diabetic polyneuropathy in 15 patients. A scored clinical evaluation and an indexed electrophysiological examination were done at inclusion, and after 3 and 6 months. Mean clinical score and electrophysiological index was improved after 3 months of therapy, the improvement persisting at 6 months, with no change in control of diabetes. These results could be related to the vasodilating properties of the drug, causing an increase in nerve temperature, or to a specific neurotropic action, as recently demonstrated in rats. Controlled studies are necessary to confirm these results, and explore the mechanism of this improvement.
Doucet
J
J
Service de Médecine Interne-Diabétologie, CHU de Rouen, Hôpital de Boisguillaume.
Senant
J
J
Ménard
J F
JF
Fresel
J
J
Schrub
J C
JC
D000328:Adult; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009257:Nafronyl / Q000008:administration & dosage / Q000627:therapeutic use*; D011115:Polyneuropathies / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
D009257:Nafronyl
Amélioration de la polynévrite diabétique sous naftidrofuryl. Résultats préliminaires.